4.4 Article

Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis

Journal

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Volume 32, Issue 3, Pages 369-389

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2019.01.002

Keywords

Ankylosing spondylitis; Axial spondyloarthritis; Psoriatic arthritis; Cardiovascular disease; Atherosclerosis; Arrhythmias; Aortic root

Categories

Funding

  1. University of Washington
  2. ASAS international society
  3. Spondylitis Association of America
  4. Russel Engelman Rheumatology Research Center at the University of California, San Francisco

Ask authors/readers for more resources

The cardiovascular burden in inflammatory rheumatic diseases is well recognized. Recently, this burden has been highlighted in ankylosing spondylitis (also known as radiographic axial spondy-loarthritis) and psoriatic arthritis. We review the cardiovascular morbidity and mortality in these diseases, as well as the prevalence and incidence of traditional cardiovascular risk factors. We examine the contribution of anti-inflammatory therapy with nonsteroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and TNF inhibitors on the cardiovascular risk profile. Finally, we examine the available recommendations for the management of cardiovascular comorbidity, as they apply to the spondyloarthritis population. (C) 2019 Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available